Ximelagatran: A novel oral direct thrombin inhibitor for long-tern anticoagulation

Reviews in Cardiovascular Medicine

Volumn 5, Issue 2, 2004, Pages 99-103

  McCullough, Peter A ^a   Dorrell, Kimberly A ^a   Sandberg, Kreisha R ^a   Yerkey, Michael W ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Chronic anticoagulation; Melagatran; Thrombin; Venous thromboembolism; Ximelgatran

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; DALTEPARIN; MELAGATRAN; PLACEBO; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; BLEEDING DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; HEART ATRIUM FIBRILLATION; HUMAN; LIVER DYSFUNCTION; LIVER INJURY; LONG TERM CARE; MODULATION; NONHUMAN; ORTHOPEDIC SURGERY; PATIENT MONITORING; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; STROKE; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; HUMANS; PRODRUGS; THROMBIN; THROMBOEMBOLISM;

EID: 3042628323     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131:927-934.
2. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003;59:35-43.
3. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res. 1999;94:187-197.
4. Carlsson S, Elg M, Mattsson C. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. Thromb Res. 2002;107:163-168.
5. Eriksson BI, Carlsson S, Halvarsson M, et al. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost. 1997;78:1404-1407.
6. Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for thrombin inhibition in orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002;360:1441-1447.
7. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89:288-296.
8. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002;137:648-655.
9. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349:1703-1712.
10. Schulman S, Wåhlander K, Lundström T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721.
11. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431-448.
12. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003;41:1445-1451.
13. Halperin JL on behalf of the SPORTIF III Investigators. SPORTIF III: a long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Late Breaking Clinical Trials III. American College of Cardiology 52nd Annual Scientific Sessions, Chicago; 2003.
14. Halperin JL on behalf of the SPORTIF V Investigators. Efficacy and safety study of oral direct thrombin inhibitor ximelagatran compared with dose-adjusted warfarin in the prevention of stroke and systemic embolic events in patients with atrial fibrillation (SPORTIF V). Plenary Session VII: Late Breaking Clinical Trials, American Heart Association Scientific Session, Orlando, FL, November 11, 2003.